Page 2 - Cellright Technologies News Today

Investegate announcements from Tissue Regenix Group, Director/PDMR Shareholding

Investegate announcements from Tissue Regenix Group, Director/PDMR Shareholding

Investegate announcements from Tissue Regenix Group, Additional Director Disclosures

About Tissue Regenix ( www.tissueregenix.com ) Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The companys patented decellularisation (dCELL®) technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patients body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinica...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

28 April 2021 | 09:29am StockMarketWire.com - Regenerative medical devices company Tissue Regenix posted a deeper annual loss as sales slipped and it wrote down the value of its CellRight Technologies business, acquired in 2017. Pre-tax losses for the year through December amounted to £10.2 million, compared to year-on-year losses of £7.7 million, and included a £6.1 million impairment charge on CellRight. Revenue fell 1.6% to £12.8 million, while gross profit fell 2% to £5.9 million. 2020...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

About Tissue Regenix ( www.tissueregenix.com ) Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The companys patented decellularisation (dCELL®) technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patients body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such...